Decentralized Clinical Trials: From On-Site to Online

Decentralized clinical trials (DCTs) are transforming patient experience by eliminating one of the most persistent barriers to participation: geography. By reducing on-site visits, DCTs lower travel burdens, cut carbon emissions, and free up significant time for patients. This shift also improves inclusivity - individuals who would not normally participate due to location, mobility limitations, or transportation barriers can now join studies from home, broadening the diversity and representativeness of clinical research.

For sponsors and clinical teams, the benefits extend well beyond logistics. Remote monitoring and digital health technologies simplify clinical data management, allowing study teams to collect, track, and validate patient data in real time without compromising quality or integrity. Decentralization also reduces the impact on clinical data management workflows by streamlining remote data capture and reducing reliance on paper-based or site-dependent processes. The result: lower costs associated with on-site clinical staff and infrastructure, with no sacrifice to timelines or oversight rigor.

Dassault Systèmes supports this evolution with life sciences manufacturing and healthcare solutions that help organizations design, deploy, and scale decentralized trial models with confidence.

The FDA plays a central role in shaping how personalized healthcare is designed, validated, and delivered, particularly as clinical research evolves toward more patient-centric, decentralized models. The agency provides regulatory guidance covering decentralized trial design, remote trial visits, digital health technologies, informed consent, and institutional review board (IRB) oversight, giving organizations a framework to innovate while maintaining compliance.

Importantly, the FDA is moving away from rigid trial classifications, such as "DCT" or "hybrid DCT" as discrete categories and instead focusing on the specific elements of decentralization that matter most for patient safety and data integrity. This shift reflects a broader regulatory acknowledgment that flexible, technology-enabled trial models are becoming the standard rather than the exception.

Pharmaceutical traceability is another area where the FDA's guidance is critical. Ensuring that drugs, devices, and patient data remain fully traceable throughout a decentralized trial is essential for meeting regulatory standards and protecting participants. As trials grow in scale and complexity, robust traceability systems become foundational to maintaining both compliance and patient trust.

AI and virtual twins represent a defining moment in healthcare evolution - one that is fundamentally changing how clinical trials are designed, run, and scaled. By creating dynamic digital replicas of patients, organs, or biological systems, virtual twins enable researchers to model disease progression, predict treatment responses, and identify risks before a single real-world intervention takes place.

At the core of this acceleration is the power of simulation and modeling. Rather than relying solely on large patient cohorts to generate statistically significant data, clinical teams can use virtual environments to run thousands of scenario permutations rapidly, compressing timelines that would otherwise take years. Dassault Systèmes' Living Heart Model is one example of how high-fidelity simulation is already being applied in life sciences to replicate cardiovascular behavior and evaluate medical device performance with precision.

These capabilities directly enable more cost-effective trials by reducing the number of physical trial phases required, minimizing adverse event risks through pre-trial virtual screening, and optimizing protocol design before recruitment even begins. The result is leaner, faster, and safer research.

Looking ahead, the virtual future of clinical research will increasingly combine AI-driven predictive analytics with virtual twin infrastructure, shifting the industry from reactive data collection to proactive, intelligent trial design.

Decentralized clinical trials are emerging as a powerful lever within a broader circular healthcare framework - one that seeks to reduce waste, minimize resource consumption, and align healthcare operations with planetary boundaries. At the most direct level, DCTs significantly reduce transportation-related carbon emissions by minimizing on-site visits and the patient travel that comes with them.

In practice, this is enabled by policies such as Bring Your Own Device (BYOD), which allows patients to use their own smartphones, tablets, or computers to upload medical data remotely, eliminating the need for repeated trips to clinical trial sites. The environmental gains are tangible: in one case enabled by MEDIDATA on the 3DEXPERIENCE® platform, over 7.5 million kilometers of travel were avoided across 15,000+ patients, resulting in a 73% reduction in emissions.

The environmental case for DCTs also intersects with the economic and regulatory landscape shaping life sciences today. Regulators and investors alike are increasingly scrutinizing the sustainability credentials of clinical operations, making emission reduction not just an ethical imperative but a compliance and competitive one.

Beyond trials themselves, the principles behind DCT design are informing the development of circular medical devices - hardware and technology ecosystems built for longevity, reuse, and minimal environmental footprint, signaling that sustainability is becoming embedded across the full clinical research value chain.